Zoetis Inc. Foreign Income Tax Expense (Benefit), Continuing Operations
Zoetis Inc. (ZTS) reported Foreign Income Tax Expense (Benefit), Continuing Operations of $278.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations · last filed 2026-02-12
- Zoetis Inc. foreign income tax expense (benefit), continuing operations for fiscal 2025 was $278.00M, a 4.51% increase from fiscal 2024.
- Zoetis Inc. foreign income tax expense (benefit), continuing operations for fiscal 2024 was $266.00M, a 13.19% increase from fiscal 2023.
- Zoetis Inc. foreign income tax expense (benefit), continuing operations for fiscal 2023 was $235.00M.
- Zoetis Inc. foreign income tax expense (benefit), continuing operations for fiscal 2016 was $152.00M, a 245.45% increase from fiscal 2015.
| Period end | Foreign Income Tax Expense (Benefit), Continuing Operations 12 month |
|---|---|
| 2025-12-31 | $278.00M 10-K · filed 2026-02-12 |
| 2024-12-31 | $266.00M 10-K · filed 2026-02-12 |
| 2023-12-31 | $235.00M 10-K · filed 2026-02-12 |
| 2016-12-31 | $152.00M 10-K · filed 2017-02-16 |
| 2015-12-31 | $44.00M 10-K · filed 2017-02-16 |
| 2014-12-31 | $58.00M 10-K · filed 2017-02-16 |
| 2013-12-31 | $100.00M 10-K · filed 2016-02-24 |
| 2012-12-31 | $133.00M 10-K · filed 2015-02-27 |
| 2011-12-31 | $172.00M 10-K · filed 2014-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |